- MorphoSys, Novartis sign antibody agreement
- Novartis teams up with Alnylam to create RNAi-based drugs; deal assigned to Arrowhead
- Myogen, Novartis Institutes in cardiovascular drug deal
- Cellzome and Novartis develop new drug candidates; concluded
- Novartis, Hybridon team up for asthma, allergy drugs; ends
- Ablynx and Novartis collaborate on Nanobodies
- Astex, Novartis ally in developing oncology drugs
- Novartis partners with SGX to develop cancer therapeutics
- Novartis signs small-molecule deal with Infinity
- Novartis, Infinity team up for cancer collaboration
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.